Early Treatment for HIV
- 5 April 1990
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (14) , 1000-1002
- https://doi.org/10.1056/nejm199004053221409
Abstract
Serologic testing for the human immunodeficiency virus (HIV) has shown that millions of persons are infected worldwide. What proportion of these will have progression to symptomatic and indeed fatal disease, and at what rate, are critical questions.Meticulous studies of the virologic features and natural history of HIV infection are now providing answers and a grim vision of the future. Viral replication can be detected even while infection appears to be clinically quiescent, and it increases enormously as clinical disease approaches.1 In approximately half the persons infected with HIV, the acquired immunodeficiency syndrome (AIDS) develops within a 10-year period.2 Although . . .Keywords
This publication has 7 references indexed in Scilit:
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- The Prognostic Value of Cellular and Serologic Markers in Infection with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1990
- Quantitation of Human Immunodeficiency Virus Type 1 in the Blood of Infected PersonsNew England Journal of Medicine, 1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989
- Survival Experience Among Patients With AIDS Receiving ZidovudinePublished by American Medical Association (AMA) ,1988
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987